The activity, protein, and mRNA expression of CYP2E1 and CYP3A1 in rats after exposure to acute and chronic high altitude hypoxia

High Altitude Medicine and Biology

Volumn 15, Issue 4, 2014, Pages 491-496

  Li, Xiangyang ^a   Wang, Xuejun ^b   Li, Yongping ^a   Zhu, Junbo ^a   Su, Xiaodong ^a   Yao, Xingchen ^a   Fan, Xueru ^a   Duan, Yabin ^a  

^a QINGHAI UNIVERSITY   (China)

^b Qinghai Red Cross Hospital   (China)

Author keywords

CYP2E1; CYP3A1; expression; high altitude; hypoxia

Indexed keywords

CHLORZOXAZONE; CYTOCHROME P450 2E1; CYTOCHROME P450 3A1; DRUG METABOLIZING ENZYME; MESSENGER RNA; TESTOSTERONE; CYP3A1 PROTEIN, RAT; CYTOCHROME P450 3A;

ACUTE HIGH ALTITUDE HYPOXIA; ALTITUDE DISEASE; ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CHRONIC HIGH ALTITUDE HYPOXIA; CONTROLLED STUDY; ENVIRONMENTAL EXPOSURE; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IN VIVO STUDY; LIVER MICROSOME; LONG TERM EXPOSURE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; RAT; REAL TIME POLYMERASE CHAIN REACTION; RNA ISOLATION; ACUTE DISEASE; ALTITUDE; ANIMAL; BLOOD; CHRONIC DISEASE; ENZYMOLOGY; GENE EXPRESSION; MALE; METABOLISM; RANDOMIZATION; SPRAGUE DAWLEY RAT;

ACUTE DISEASE; ALTITUDE; ALTITUDE SICKNESS; ANIMALS; CHLORZOXAZONE; CHRONIC DISEASE; CYTOCHROME P-450 CYP2E1; CYTOCHROME P-450 CYP3A; FEMALE; GENE EXPRESSION; MALE; MICROSOMES, LIVER; RANDOM ALLOCATION; RATS; RATS, SPRAGUE-DAWLEY; RNA, MESSENGER; TESTOSTERONE;

EID: 84919627883     PISSN: 15270297     EISSN: 15578682     Source Type: Journal    
DOI: 10.1089/ham.2014.1026     Document Type: Article

References (37)

1. Arancibia A, Paulos C, Chavez J, and Ritschel WA. (2003). Pharmacokinetics of lithium in healthy volunteers after exposure to high altitude. Int J Clin Pharmacol Ther 41: 200-206.
2. Bleau AM, Levitchi M, Maurice H, Duplain H. (2000). Cytochrome P450 inactivation by serum from humans with a viral infection and serum from rabbits with a turpentine-induced inflammation: The role of cytokines. Br J Pharmacol 130: 1777-1784.
3. Duplain H, Sartori C, and Scherrer U. (2007). High altitude related illness. Rev Med Suisse 3: 1766-1769.
4. Eichelbaum M, Koremer NK, and Mikus G. (1992). Genetically determined differences in drug metabolism as a risk factor in drug toxicity. Toxicol Lett 64: 115-122.
5. Fradette C, Bleau AM, Pichette V, Chauret N, and Du Souich P. (2002). Hypoxia-induced down-regulation of CYP1A1/1A2 and up-regulation of CYP3A6 involves serum mediators. Br J Pharmacol 137: 881-891.
6. Fradette C, and Du SP. (2003). Hypoxia-inducible factor-1 and activator protein-1 modulate the upregulation of CYP3A6 induced by hypoxia. Brit J Pharma 140: 1146-1154.
7. Fradette C, and Du SP. (2004). Effect of hypoxia on cytochrome P450 activity and expression. Curr Drug Metab 5: 257-271.
8. Fradette C, Batonqa J, Teng S, Piquette-Miller M, and Du Souich P. (2007). Animal models of acute moderate hypoxia are associated with a down-regulation of CYP1A1, 1A2, 2B4, 2C5, 2C16 and up-regulation of CYP3A6 and p-glycoprotein in liver. Drug Metab Dispos 35: 765-771.
9. Gallagher SA, and Hackett PH. (2004). High altitude illness. Emerg Med Clin North Am 22: 329-355.
10. Guengerich FP. (1995). Cytochrome P450. New York: Plenum Press.
11. He F, Bi HC, Xie ZY, Zuo Z, Li JK, Li X, Zhao LZ, Chen X, Huang M. (2007). Rapid determination of six metabolites from multiple cytochrome P450 probe substrates in human liver microsome by liquid chromatography/mass spectrometry: Application to high throughput inhibition screening of terpenoids. Rapid Commun Mass Sp 21: 635-643.
12. Heistad DD, Abboud FM, and Dickinson W. (1980). Richards lecture: Circulatory adjustments to hypoxia.Circulation 61: 463-470.
13. Jones DP. (1981). Hypoxia and drug metabolism. Biochem Pharmacol 30: 1019-1023.
14. Jones DP, Aw TY, and Shan X. (1989). Drug metabolism and toxicity during hypoxia. Drug Metab Rev 20: 247-260.
15. Kurdi J, Maurice H, El-Kadi AO, Ong H, Dalkara S, BelangerPM, and Souich P. (1999). Effect of hypoxia alone or combined with inflammation and 3-methylcholanthrene on hepatic cytochrome P450 in conscious rabbits. Br J Pharmacol 128: 365-373.
16. Lacombe C, and Mayeux P. (1999). The molecular biology of erythropoietin. Nephrol Dial Transpl 14 (Suppl. 2): 22-28.
17. Letarte L, and Du SP. (1984). Influence of hypercapnia and/or hypoxemia and metabolic acidosis on theophylline kinetics in the conscious rabbit. Am Rev Respir Dis 129: 762-766.
18. Li XY, Gao F, Li ZQ, Guan W, Feng WL, Ge RL. (2009). Comparison of the pharmacokinetics of sulfamethoxazole in male Chinese volunteers at low altitude and acute exposure to high altitude versus subjects living chronically at high altitude: An open-labeled, controlled, prospective study. Clin Ther 31: 2744-2754.
19. Li XY, Liu YN, Wang XJ, Zhu JB, Yuan M, Li YP, Li YF. (2012). Comparison of the pharmacokinetics of sulfamethoxazole in native Han and Tibetan male Chinese volunteers living at high altitude. Eur J Drug Metab Pharmacokinet 37: 263-269.
20. Li XY, Liu YN, Yuan M, Li YP, Yang YZ, Zhu JB. (2012). The effect of high altitude hypoxia on the activity and protein expression of CYP2C9 andCYP2C19. Acta Pharm Sin 47: 188-193.
21. Li XY, Wang XJ, Li YP, Yuan M, Zhu JB, Su XD, Yao XC, Fan XR, Duan YB. (2014). Effect of exposure to acute and chronic high altitude hypoxia on the activity and expression of CYP1A2, CYP2D6, CYP2C9, CYP2C19 and NAT2 in rats. Pharmacology 93: 76-83.
22. Luks AM, and Swenson ER. (2008). Medication and dosage considerations in the prophylaxis and treatment of high altitude illness. Chest 133: 744-755.
23. Mairbaurl H. (1994). Red blood cell function in hypoxia at altitude and exercise. Int J Sports Med 15: 51-63.
24. Morgan ET. (1997). Regulation of cytochromes P450 during inflammation and infection. Drug Metab Rev 29: 1129-1188.
25. Naldini A, Carraro F, Silvestri S, and Bocci V. (1997). Hypoxia affects cytokines production and proliferative responses by human peripheral mononuclear cells. J Cell Physiol 173: 335-342.
26. Rahman MS, and Thomas P. (2003). Effects of hypoxia exposure on hepatic cytochrome P450 1A (CYP1A) expression in Atlantic croaker: Molecular mechanisms of CYP1A downregulation. PLoS ONE 7: e40825.
27. Rowell LB, Blackmon JR, Kenny MA, and Escourrou P. (1984). Splanchnic vasomotor and metabolic adjustments to hypoxia and exercise in humans. Am J Physiol 247: 251-258.
28. Saunier C, Du Souich P, Hartemann D, and Sautegeau A. (1987). Theophylline disposition during acute and chronic hypoxia in the conscious dog. Res Commun Chem Pathol Pharmacol 57: 291-299.
29. Semenza GL. (1999).Regulation ofmammalianO2 homeostasis by hypoxia-inducible factor 1. Annu Rev Cell Dev Biol 15: 55-78.
30. Shan X, Aw TY, Smith ER, Ingelman-Sundberg M, Mannervik B, Iyanagi T, and Jones DP. (1992). Effect of chronic hypoxia on detoxication enzymes in rat liver. Biochem Pharmacol 43: 2421-2426.
31. Streit M, Goggelmann C, Dehnert C, Burhenne J, Riedel KD, Menold E, Mikus G, Bartsch P, and Haefell WE. (2005). Cytochrome P450 enzyme-mediated drug metabolism at exposure to acute hypoxia (corresponding to an altitude of 4, 500 m). Eur J Clin Pharmacol 61: 39-46.
32. Sutton JR, Reeves JT, Wagner PD, Groves BM, Cymerman A, Malconian MK, Rock PB, Young PM, Walter SD, and Houston CS. (1988). Operation Everest II: Oxygen transport during exercise at extreme simulated altitude. J Appl Physiol 64: 1309-1321.
33. Vesell ES. (1977). Genetic and environmental factors affecting drug disposition in man. Clin Pharmacol Ther 22: 659-679.
34. Wolff CB. (2000). Cerebral blood flow and oxygen delivery at high altitude. High Alt Med Biol 1: 33-38.
35. Yang M, Zhu JB, Li YP, Fan XR, Yuan M, Li XY. (2013). The effect of high altitude hypoxia on the activity of NAT2 in rats. J Qinghai Med Coll 34: 79-83.
36. Yasui H, Deo K, Ogura Y, Yoshida H, Shiraga T, Kagayama A, Sakurai H. (2002). Evidence for singlet oxygen involvement in rat and human cytochrome P450-dependent substrate oxidations. Drug Metab Pharmacokin 17: 416-426.
37. Zhang YB, Wang Y, and Liu XL. (1984). Mountain Sickness. Xining: Publishing House of Qinghai People.